GE HealthCare Technologies Inc. Common Stock vs KKR & Co Inc — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while KKR & Co Inc trades at $85.5 (market cap $78.24B). The key difference: KKR & Co Inc is far larger — about 2.5× GE HealthCare Technologies Inc. Common Stock's market cap, and KKR & Co Inc pays the higher dividend (0.89%). Which is the better fit depends on your goals.
| GEHC | KKR | |
|---|---|---|
Market Cap | $31.07B | $78.24B |
Volume | 3,443,020 | 9,217,096 |
Sector | Health | Financials |
52-Week High | $88.16 | $142.75 |
52-Week Low | $59.48 | $83.88 |
Enterprise Value | $39.53B | $795.68M |
Dividend Yield | 0.23% | 0.89% |
Typical Hold Time | — | 67 Days |
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
KKR's stock is trading at $85.60, down 6.46% in the last session amid a bearish technical outlook. The company maintains strong profitability with a 14.97% net income margin and has beaten earnings estimates in two of the last three quarters. Recent business developments include multiple strategic investments and joint ventures, including a partnership with Thomson Reuters and new equipment finance platform Akrapoint Commercial Capital.
Despite near-term price weakness, KKR presents a compelling investment case with strong analyst support (88.9% buy ratings) and a consensus price target of $123.20 representing 44% upside. Key risks include volatile cash flow patterns and high leverage, but the company's diversified investment platform and active deal pipeline support long-term growth prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →